Jelle Barentsz, MD, presented “Usefulness of Adjustable Needle Sizes for Biopsies” for the Grand Rounds in Urology audience during a break at the 30th Annual International Prostate Cancer Update in January, 2020.
How to cite: Barentsz, Jelle. “Usefulness of Adjustable Needle Sizes for Biopsies” January, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/usefulness-of-adjustable-needle-sizes-for-biopsies/
Usefulness of Adjustable Needle Sizes for Biopsies – Summary:
E. David Crawford, MD, Professor of Urology at the University of California, San Diego, discusses the usefulness of adjustable needle sizes for prostate biopsies with Jelle Barentsz, MD, PhD, Professor of Radiology at the Nijmegen Medical Center of Radboud University in Nijmegen, The Netherlands. Dr. Barentsz agrees with Dr. Crawford that a needle that can be adjusted from 10 to 60 gauge would be useful in situations such as when the smaller needle sometimes needed to reach an area is unable to pierce through fat to take the needed core sample. Drs. Barentsz and Crawford then address the pros and cons of mapping biopsy of the prostate: Dr. Barentsz contends that the use of 180 needles to obtain only slightly more accurate results than MRI may not be warranted, and Dr. Crawford notes that mapping biopsies are usually reserved for patients with negative MRIs and negative biopsies.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Barentsz & Dr. Crawford discussed this topic during a break at the 30th iteration of the meeting in January 2020.
Other parts of this interview include:
What Does Suspicion for Prostate Cancer Mean, and What Metric Defines Prostate Cancer Risk?
Are MRI Fusion Biopsies Necessary for Urologists?
The Capacity of MRI to Predict Extracapsular Disease
The Use of MRI to Determine the Target for Focal Therapy
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Jelle Barentsz, MD, PhD, is a Professor of Radiology at the Nijmegen Medical Center of Radboud University in Nijmegen, The Netherlands. He is an internationally recognized researcher known for developing, validating, and implementing new MRI techniques in oncology. He is also the Chair of the Prostate MR-Reference Center, Founding Member and Past-President of the International Cancer Imaging Society, and Past-President of the European Society of Urogenital Radiology (ESUR). In 1980, he earned his MD from Utrecht University. In 1990, he earned his PhD in medical research on MRI of the urinary bladder from Radboud University Nijmegen. Since then, he has contributed to almost 300 peer-reviewed publications. One of his notable contributions involves initiating PI-RADS and, along with ESUR and the American College of Radiology, making the system a world standard, thereby enabling early selective detection of aggressive prostate cancer. Also, he helped revive Combidex-MRI, which can detect 1.5 mm lymph node metastases of any cancer.
He has been decorated as a “Knight in the Order of the Dutch Lion.” In addition, he has been awarded the Wertheim Salomonson Medal, the SAR Lifetime Achievement Award, the Dutch Cancer Society’s Queen Wilhelmina Research Award, and the SCBTMR Lauterbur Award.
